Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Federal Trade Commission
Accenture
Fish and Richardson
Colorcon
QuintilesIMS
Medtronic
Merck
Healthtrust

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020401

« Back to Dashboard

NDA 020401 describes TIAZAC, which is a drug marketed by Valeant Pharms North and is included in one NDA. It is available from eight suppliers. Additional details are available on the TIAZAC profile page.

The generic ingredient in TIAZAC is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.
Summary for 020401
Tradename:TIAZAC
Applicant:Valeant Pharms North
Ingredient:diltiazem hydrochloride
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020401
Mechanism of ActionCalcium Channel Antagonists
Suppliers and Packaging for NDA: 020401
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401 NDA Valeant Pharmaceuticals North America LLC 0187-2612 N 0187-2612-30
TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401 NDA Valeant Pharmaceuticals North America LLC 0187-2612 N 0187-2612-90

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength120MG
Approval Date:Sep 11, 1995TE:AB4RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength180MG
Approval Date:Sep 11, 1995TE:AB4RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength240MG
Approval Date:Sep 11, 1995TE:AB4RLD:Yes

Expired US Patents for NDA 020401

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-002 Sep 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-003 Sep 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-004 Sep 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-001 Sep 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Colorcon
Daiichi Sankyo
Argus Health
QuintilesIMS
AstraZeneca
Medtronic
Express Scripts
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.